Home
>
US Stocks
>
Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc.
HALO

Halozyme Therapeutics Inc. (HALO)

$38.93.45%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
38.43
Today Low/High
38.43 / 39.12
52 Week Low/High
$25.17 / $56.4
P/E ratio
25.34
Market Cap
$5.8B

Company Details

Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx and Horizon Therapeutics. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company's partners make progress developing and commercializing their products being developed with ENHANZE®. Halozyme is headquartered in San Diego.
Organisation
Halozyme Therapeutics Inc.
Headquaters
San Diego, California, US
Employees
136
Industry
Health Technology
CEO
Helen Torley

Discover more

Frequently Asked Questions

What is Halozyme Therapeutics Inc. (HALO) share price today?

Can Indians buy Halozyme Therapeutics Inc. (HALO) shares?

How can I buy Halozyme Therapeutics Inc. (HALO) shares from India?

Can Fractional shares of Halozyme Therapeutics Inc. (HALO) be purchased?

What are the documents required to start investing in Halozyme Therapeutics Inc. (HALO) stocks?

We are a SEBI registered investement advisor